Last reviewed · How we verify
NCT01037569
Optimizing Toxicological Screening in Drug Endangered Children
trial in Substance Abuse Detection in 100 participants. Completed in 22 March 2011.
Quick facts
| Lead sponsor | National Institute on Drug Abuse (NIDA) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 10 July 2007 |
| Estimated completion | 22 March 2011 |
| Sites | 1 location across United States |
Conditions studied
- Substance Abuse Detection — all drugs for Substance Abuse Detection →
Sponsor
National Institute on Drug Abuse (NIDA)
Who can join
Adults 1 to 18, any sex, with Substance Abuse Detection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: * Children who enter the foster care system are all too often exposed to illicit drugs in the home. Children from these homes, known as drug endangered children, are not routinely tested for harmful substances. Any short- and long-term physical or developmental problems they may experience as a result of this exposure often go undetected and untreated. * Children who are placed into protective custody are not always screened by physicians or nurse practitioners. Although drug-endangered children under 18 years of age automatically receive a urine toxicology screen to determine the types and levels of illicit drugs in their systems, this procedure has difficulties and limitations that may affect the quality of the data. Researchers are interested in developing more effective methods of analyzing the presence or absence of illicit environmental drug exposure in children. Objectives: \- To determine the most effective method of identifying long-term illicit stimulant drug exposure in drug-endangered children. Eligibility: \- Children under 18 years of age who are being placed into protective custody after having been found in a home where drugs are manufactured, used, or sold. Design: * Researchers will gain verbal consent for the procedure for children who are 7 years of age or older. Children younger than 7 years of age will not be required to give verbal consent for sample collection. * Researchers will collect standard urine samples for toxicological screening. Part of the sample will be sent to the National Institute on Drug Abuse for evaluation; the rest will remain with the local authority. * In addition to this standard procedure, researchers will collect a hair sample by cutting a small amount of hair from the crown of the head as close to the root as possible (and not pulling any hair out of the child's head). * Researchers will also use an oral swab to collect a saliva sample from the inside cheek of each child. * No clinical care will be provided under this protocol....
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01037569
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Institute on Drug Abuse (NIDA) trials
Trials by the same sponsor.
- NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT06808932 — VK4-116 Phase I Study With Food-Effect · Phase 1 · not yet recruiting
- NCT06676059 — SMART-r: Substance Monitoring and Active Relapse Tracking Repository · recruiting
- NCT06577454 — Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Sub · NA · suspended
- NCT06868914 — Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01037569 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA)
- Last refreshed: 2 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01037569.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing